SCHEMBL1553078

SCHEMBL1553078

COC(=O)c1ccc(-c2csc(N)n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.67
KDM4E B2RXH2 2/20 0.67
MAPT P10636 7/20 0.59
RAB9A P51151 7/20 0.59
NPC1 O15118 5/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
POLB P06746 2/20 0.59
LTA4H P09960 4/20 0.56
MKNK1 Q9BUB5 1/20 0.56
MKNK2 Q9HBH9 1/20 0.56
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
MYC P01106 1/20 0.52
WDR5 P61964 1/20 0.52
LMNA P02545 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
ALOX5 P09917 1/20 0.51
MAPK14 Q16539 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22801073 0.88 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL28705905 0.84 MEN1 (0.53) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL5350275 0.84 RAB9A (0.68) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL3938751 0.84 FBP1 (0.55) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL4743571 0.84 ALDH1A1 (0.61) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL1811618 0.83 MAPT (0.52) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL3134349 0.82 ALDH1A1 (0.73) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL24590300 0.82 MAPT (0.60) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL29674702 0.81 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTRAB9ANPC1
SCHEMBL13626237 0.81 ALDH1A1 (0.61) ALDH1A1KDM4EMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
WO-2022147694-A1 AMINOHETEROARYL COMPOUNDS AND USES THEREOF BEIJING ERAI THERAPEUTICS CO., LTD. (CN) 2022-07-14 WO disclosed
WO-2022148331-A1 AMINOHETEROARYL COMPOUNDS AND USES THEREOF BEIJING ERAI THERAPEUTICS CO., LTD. (CN) 2022-07-14 WO disclosed
CN-113912617-A Substituted tricycles and methods of use 艾伯维公司 2022-01-11 CN disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-108349930-B Substituted tricycles and methods of use 艾伯维公司 2021-10-29 CN disclosed
CN-1745071-A Novel ethylenediamine derivative DAIICHI SEIYAKU CO (JP) 2006-03-08 CN disclosed
EP-1031563-B1 SULFONYL DERIVATIVES DAIICHI SEIYAKU CO (JP) 2005-12-28 EP disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
US-20030232808-A1 Sulfonyl derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-12-18 US disclosed
US-6525042-B1 Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-02-25 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed
CN-1278793-A Sulfonyl derivatives DAIICHI SEIYAKU CO (JP) 2001-01-03 CN disclosed
EP-1031563-A1 SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 ALDH1A1 2267/4885KDM4E 1848/4885MAPT 706/4885
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 ALDH1A1 1316/4885KDM4E 3346/4885MAPT 4665/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 ALDH1A1 2267/4885KDM4E 1848/4885MAPT 706/4885
US-20030232808-A1 Sulfonyl derivatives SULT1E1, SULT2A1, SULT1A1 ALDH1A1 2493/4885KDM4E 2189/4885MAPT 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.